DUBLIN–(BUSINESS WIRE)–Feb 19, 2021–
The "Inflammation and Pain Post Cataract Surgery – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Inflammation and Pain Post Cataract Surgery pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A cataract is a dense cloudy area that forms in the lens of the eye. The problem is common in older people. It is the most common cause of vision loss in developed and developing countries. Cataract surgery is the most commonly performed surgical procedure. The minimally invasive cataract surgery technique with phacoemulsification is considered to be a minor procedure with less complications. However, post-operative problems such as ocular pain and inflammation can cause some problems. Despite surgical advances, post-cataract surgery inflammation is still a common cause of patient discomfort, delayed recovery and reduced visual outcome.
"Inflammation and Pain Post Cataract Surgery – Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammation and Pain Post Cataract Surgery pipeline landscape is provided which includes the disease overview and Inflammation and Pain Post Cataract Surgery treatment guidelines. The assessment part of the report embraces, in depth Inflammation and Pain Post Cataract Surgery commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inflammation and Pain Post Cataract Surgery collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Inflammation and Pain Post Cataract Surgery Emerging Drugs Chapters
This segment of the Inflammation and Pain Post Cataract Surgery report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Inflammation and Pain Post Cataract Surgery: Therapeutic Assessment
This segment of the report provides insights about the different Inflammation and Pain Post Cataract Surgery drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Inflammation and Pain Post Cataract Surgery
There are approx. 5+ key companies which are developing the therapies for Inflammation and Pain Post Cataract Surgery. The companies which have their Inflammation and Pain Post Cataract Surgery drug candidates in the mid to advanced stage, i.e. phase III include, Xigen and others.
The report covers around 5+ products under different phases of clinical development like
- Late-stage products (phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Inflammation and Pain Post Cataract Surgery pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Topical
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Inflammation and Pain Post Cataract Surgery: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammation and Pain Post Cataract Surgery therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammation and Pain Post Cataract Surgery drugs.
Inflammation and Pain Post Cataract Surgery Report Insights
- Inflammation and Pain Post Cataract Surgery Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Inflammation and Pain Post Cataract Surgery Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Inflammation and Pain Post Cataract Surgery drugs?
- How many Inflammation and Pain Post Cataract Surgery drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammation and Pain Post Cataract Surgery?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inflammation and Pain Post Cataract Surgery therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Inflammation and Pain Post Cataract Surgery and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Xigen
- Formosa Pharmaceuticals
- Oculis Pharma
- Surface Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cq023m
View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005349/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: PHARMACEUTICAL OPTICAL HEALTH SURGERY
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/19/2021 10:02 AM/DISC: 02/19/2021 10:02 AM
http://www.businesswire.com/news/home/20210219005349/en
